Please login to the form below

Not currently logged in


This page shows the latest antiplatelet news and features for those working in and with pharma, biotech and healthcare.

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Overall, BMS reported an 8% increase in revenues to $5.7bn, with gains for Opdivo and Yervoy (up 18% to $382m) accompanied by a good performance from antiplatelet drug Eliquis (apixaban)

Latest news

More from news
Approximately 3 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Why health psychology is the answer to tackling adherence Why health psychology is the answer to tackling adherence

    In one recent programme that we developed on behalf of AstraZeneca, we assessed the reasons for low adherence in patients with acute coronary syndrome (ACS) who had been prescribed Oral Antiplatelet

  • Who tops the pharma list? Who tops the pharma list?

    The latter, an antiplatelet agent it co-marketed with Sanofi, enjoyed 2011 sales of $9.4bn - but, with Plavix accounting for more than a third of BMS revenues in 2010, the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company Conferences, Events and Exhibition Stands is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...